Non-Small Cell Lung Cancer, cutaneous melanoma, urothelial cancer, research hub

An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors

This study is testing a new medicine, NECVAX-NEO1, alongside standard cancer treatments (like anti-PD-1 or anti-PD-L1 drugs). It's for people with certain solid tumours like lung cancer or melanoma. This early-stage trial aims to see if the new medicine is safe and how it works in the body.